These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


153 related items for PubMed ID: 17496448

  • 1. [Clinical study of combination chemotherapy of methotrexate, epirubicin and nedaplatin (MEN) in patients with advanced urothelial carcinoma].
    Hattori Y, Takizawa A, Kishida T, Kakizoe M, Fujikawa N, Teranishi J, Kondo K, Saito K, Noguchi K, Nakaigawa N, Kubota Y.
    Gan To Kagaku Ryoho; 2007 May; 34(5):739-43. PubMed ID: 17496448
    [Abstract] [Full Text] [Related]

  • 2. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
    Tsavaris N, Kosmas C, Skopelitis H, Dimitrakopoulos A, Kopterides P, Bougas D, Stravodimos K, Mitropoulos D, Alamanis C, Giannopoulos A.
    J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
    [Abstract] [Full Text] [Related]

  • 3. Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
    Kyriakakis Z, Dimopoulos MA, Kostakopoulos A, Karayiannis A, Sofras F, Zervas A, Giannopoulos A, Dimopoulos C.
    J Urol; 1997 Aug; 158(2):408-11. PubMed ID: 9224313
    [Abstract] [Full Text] [Related]

  • 4. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
    Hsu CH, Chen J, Wu CY, Cheng AL, Pu YS.
    Anticancer Res; 2001 Aug; 21(1B):711-5. PubMed ID: 11299831
    [Abstract] [Full Text] [Related]

  • 5. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
    Kouno T, Ando M, Yonemori K, Matsumoto K, Shimizu C, Katsumata N, Komiyama M, Okajima E, Matsuoka N, Fujimoto H, Fujiwara Y.
    Eur Urol; 2007 Oct; 52(4):1115-22. PubMed ID: 17433855
    [Abstract] [Full Text] [Related]

  • 6. [M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced renal pelvic and ureteral carcinoma].
    Igawa M, Ueki T, Ueda M, Okada K, Usui T, Ohnishi Y, Kume T, Masu C, Ishino T, Nakatsu H.
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2577-82. PubMed ID: 2673046
    [Abstract] [Full Text] [Related]

  • 7. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A, Flex D, Gafni D, Rabinovitz O, Sulkes A, Baniel J.
    Harefuah; 1999 Feb 15; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [Abstract] [Full Text] [Related]

  • 8. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
    Nakanishi S, Matsuzaki M, Morikawa H, Nakano M, Komatsu H.
    Hinyokika Kiyo; 2004 Oct 15; 50(10):667-71. PubMed ID: 15575216
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer.
    Cao W, Xu C, Lou G, Jiang J, Zhao S, Geng M, Xi W, Li H, Jin Y.
    Jpn J Clin Oncol; 2009 Sep 15; 39(9):582-7. PubMed ID: 19509000
    [Abstract] [Full Text] [Related]

  • 11. [Paclitaxel, ifosfamide, nedaplatin (TIN) for patients with metastatic urothelial cancer].
    Suzuki S, Shinohara N, Harabayashi T, Seki H, Murakumo M, Ishikawa R, Demura T, Mitsuhashi K, Toyota H, Koyanagi T.
    Gan To Kagaku Ryoho; 2004 Apr 15; 31(4):561-5. PubMed ID: 15114700
    [Abstract] [Full Text] [Related]

  • 12. [Study of neoadjuvant chemotherapy for invasive bladder cancer with MEC (methotrexate, epirubicin, cisplatin) therapy].
    Ohuchi H, Noguchi S, Takase K, Kawakami S, Ikeda I, Saito K, Yao M, Masuda M, Kubota Y, Hosaka M.
    Hinyokika Kiyo; 2001 Apr 15; 47(4):241-6. PubMed ID: 11411097
    [Abstract] [Full Text] [Related]

  • 13. [Clinical evaluation of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy for advanced urothelial cancer].
    Mikami K, Nakagawa S, Takada H, Ebisui K, Sugimoto K, Watanabe H, Maegawa M, Nakao M.
    Hinyokika Kiyo; 1994 Apr 15; 40(4):303-7. PubMed ID: 8191968
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase II study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer.
    Hirose T, Sugiyama T, Kusumoto S, Shirai T, Nakashima M, Yamaoka T, Okuda K, Ogura K, Ohnishi T, Ohmori T, Adachi M.
    Anticancer Res; 2009 May 15; 29(5):1733-8. PubMed ID: 19443395
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
    Oh WK, Manola J, Richie JP, Loughlin KR, Kantoff PW.
    Cancer; 1999 Oct 01; 86(7):1329-34. PubMed ID: 10506721
    [Abstract] [Full Text] [Related]

  • 20. [Combination chemotherapy of advanced transitional cell carcinoma with cis-platinum, cyclophosphamide, adriamycin and 5-fluorouracil (CISCAF)].
    Fujioka H, Tada Y, Nakano E, Matsuda M, Osafune M, Sagawa S, Takaha M, Sonoda T.
    Gan To Kagaku Ryoho; 1984 Aug 01; 11(8):1612-6. PubMed ID: 6541019
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 8.